Difference between revisions of "Template:HypericumInfo"
From Psychiatrienet
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
* Hypericum might have [[wp:Monoamine oxidase inhibitor|MAO-inhibiting]] and/or [[wp:COMT inhibitor|COMT-inhibiting]] properties. | * Hypericum might have [[wp:Monoamine oxidase inhibitor|MAO-inhibiting]] and/or [[wp:COMT inhibitor|COMT-inhibiting]] properties. | ||
* Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.<ref name ="Wurglics2006">{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref> | * Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.<ref name ="Wurglics2006">{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref> | ||
| − | |||
Latest revision as of 14:11, 4 August 2023
- Hypericum induces enzymes of the CYP P-450 type and P-gp type.
- Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
- Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[1]
